Rheumatology
Recommended musculoskeletal and sports ultrasound terminology: a Delphi-based consensus statement.
4 Feb, 2022 | 08:51h | UTC
Commentary on Twitter
🚨 #NEW Consensus Statement: the use of MSK and sport ultrasound terminology 🏥
A Delphi-based agreement for terminology to improve clarity and consistency in communication for education, clinical practice and research 🗣
READ the framework HERE ➡️ https://t.co/w2proNy62M pic.twitter.com/Pjfl2lRVTL
— British Journal of Sports Medicine (BJSM) (@BJSM_BMJ) February 3, 2022
Hyaluronic acid injections have increased for knee arthritis in the US, despite guideline recommendations against their use.
4 Feb, 2022 | 08:32h | UTCHyaluronic Acid Injections for Knee Osteoarthritis: Has Utilization Among Medicare Beneficiaries Changed Between 2012 and 2018? – The Journal of Bone & Joint Surgery (link to abstract – $ for full-text)
News Release: Hyaluronic acid injections have increased for knee arthritis – despite recommendations against their use
Related Guideline: Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline, 2nd Edition – Journal of the American Academy of Orthopaedic Surgeons
An observational study including 15.670 people using methotrexate and 2.689 using leflunomide showed the incidences of discontinuation related to cytopenia, liver enzyme elevation, or kidney function decline.
4 Feb, 2022 | 08:21h | UTC
Psychosis in systemic lupus erythematosus (SLE): a 40-year experience of a specialist center showed most patients (66.7%) had full remission with a combination of antipsychotics and immunosuppressive therapy.
4 Feb, 2022 | 08:20h | UTC
Review: Behçet syndrome.
3 Feb, 2022 | 08:29h | UTCBehçet syndrome – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Behçet syndrome (if the link is paywalled, try this one)
Related: EULAR recommendations for the management of Behçet’s syndrome
RCT: Efficacy and safety of Risankizumab for active psoriatic arthritis.
2 Feb, 2022 | 08:23h | UTC
Recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis.
1 Feb, 2022 | 08:44h | UTC
RCT: In patients with rheumatoid arthritis, treatment with oral drug Tofacitinib increases cardiovascular and cancer risk compared to treatment with subcutaneous TNF inhibitors.
1 Feb, 2022 | 08:35h | UTCCardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
Video: CV and Cancer Risk with Tofacitinib in RA – New England Journal of Medicine
Commentary: CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis – HealthDay
Systematic Review: Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases.
1 Feb, 2022 | 08:20h | UTC
Commentary on Twitter
What is the added value of #imaging in interventional procedures in musculoskeletal diseases?
Check out our recent systematic literature review informing EULAR points to consider
✅needle positioning
🔴 heterogeneity and risk of bias🔗 https://t.co/qdcNuKECxH@pedrommcmachado
— Annals of the Rheumatic Diseases (@eular_ARD) December 9, 2021
RCT: Vitamin D supplementation for older adults (mean age 67 years) for 5 years reduced the risk of autoimmune diseases by 22%. Absolute risk in the treatment group was 0.95% vs. 1.19% in the placebo group.
30 Jan, 2022 | 14:30h | UTCCommentary: Vitamin D and fish oil supplements may help prevent autoimmune disease, study says – CNN
Related:
USPSTF Statement: Insufficient evidence to recommend Vitamin D deficiency screening
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
30 Jan, 2022 | 14:19h | UTC
Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
30 Jan, 2022 | 14:11h | UTCOriginal Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Related:
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life.
28 Jan, 2022 | 08:30h | UTC
Review: Juvenile idiopathic arthritis.
28 Jan, 2022 | 08:13h | UTCJuvenile idiopathic arthritis – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Juvenile idiopathic arthritis (if the link is paywalled, try this one)
Commentary on Twitter
Get Primed on juvenile idiopathic #arthritis with our NEW PrimeView! FREE to download this week!https://t.co/MUVlIRWCfY pic.twitter.com/G5woxpOlKI
— Nature Reviews Disease Primers (@DiseasePrimers) January 27, 2022
Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach.
27 Jan, 2022 | 09:18h | UTC
Cohort Study: Among patients with resolved Hepatitis B infections and concomitant autoimmune disease, exposure to prednisone doses greater than 20 mg/day were associated with a high risk for HBV reactivation or hepatitis flare.
21 Jan, 2022 | 09:39h | UTCAverage corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection – Annals of Rheumatic Disease (link to abstract – $ for full-text)
Commentary on Twitter
Patients with time-weighted average prednisone dose greater than 20 mg/day would be classified as the high risk for HBV reactivation or hepatitis flare. Prophylactic Anti-HBV therapy may be needed for these high-risk patientshttps://t.co/qLuirdyXDK pic.twitter.com/yDJ4c072qm
— Annals of the Rheumatic Diseases (@eular_ARD) December 23, 2021
Systematic Review: Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis.
21 Jan, 2022 | 09:24h | UTC
Consensus statements for the assessment and management of non-radiographic axial spondyloarthritis.
21 Jan, 2022 | 09:26h | UTC
Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis.
20 Jan, 2022 | 08:52h | UTC
In a study with 1110 children with prolonged fever, MRP8/14 serum levels were validated as a diagnostic marker for systemic juvenile idiopathic arthritis.
14 Jan, 2022 | 08:07h | UTCMRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link to abstract – $ for full-text)
Commentary: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
8 Jan, 2022 | 22:45h | UTCJanus kinase-targeting therapies in rheumatology: a mechanisms-based approach – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Review: Large-vessel vasculitis.
8 Jan, 2022 | 22:50h | UTCLarge-vessel vasculitis – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Large-vessel vasculitis (if the link is paywalled, try this one)
Management of patellar tendinopathy: a systematic review and network meta-analysis of randomized studies.
16 Dec, 2021 | 08:35h | UTC